A multi-center, randomized, double-blind, placebo-controlled, multiple dose study to investigate safety and tolerability of RG1662 in individuals with Down Syndrome.
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2014
At a glance
- Drugs Basmisanil (Primary)
- Indications Behavioural symptoms; Cognition disorders; Down syndrome
- Focus Adverse reactions
- Sponsors Roche
- 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jul 2013 Planned End Date changed from 1 Jul 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 23 May 2013 Planned end date changed from 1 May 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.